All posts by Mary Jo Strobel

APFED ANNOUNCES 2017 HOPE RESEARCH GRANT RECIPIENTS

Funding supports researchers who have novel approaches to understanding eosinophilic esophagitis

(ATLANTA, GA)—The American Partnership for Eosinophilic Disorders (APFED) is pleased to announce the award of two HOPE Pilot Grants in support of promising research projects studying eosinophilic esophagitis (EoE).

The first of two awardees receiving APFED’s 2017 HOPE Pilot Grant is John Garber, MD, Instructor in Medicine, Harvard Medical School; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital. Dr. Garber will receive $100,000 over a two-year period for his project entitled, “Determinants of Integrin Signaling in Eosinophilic Esophagitis.”

Dr. Garber’s team will be studying the interaction of select integrins relative to recruitment and activation of eosinophils in the esophagus. Gaining a better understanding of the mechanisms of eosinophil recruitment may lead to the development of treatments that stop the migration of eosinophils into the esophagus.

The second 2017 HOPE Pilot Grant was awarded to Aaron Kobernick, MD, MPH, Assistant Professor, Allergy and Immunology, University of Utah. Dr. Kobernick will receive $100,000 over a two-year period for his project entitled, “Detection of Eosinophilic Inflammation in Patients with Eosinophilic Esophagitis by Oral Administration of Tc-99m Heparin.”

This research focuses on finding a noninvasive way to detect and monitor EoE.  Dr. Kobernick’s team has developed a technique in which heparin labeled with a radioactive tracer can be used with a specialized camera to identify the presence of eosinophils in the esophagus. The aim of his research will be to assess the lowest amount of radioactivity that can be used to evaluate inflammation caused by esophageal eosinophilia.

This research shows great promise as a potential noninvasive method for doctors to use to evaluate whether a particular treatment method (e.g., dietary therapy, corticosteroids) is effective for a patient.

“The grant cycle was very competitive for this year’s HOPE on the Horizon Research Program,” said APFED Executive Director Mary Jo Strobel. “We are grateful for the generous donors who recognize the importance of investing in research that enables better quality of care and life for those with eosinophil-associated diseases. Their contributions enabled two awards this year, and we are excited to support this research.”

“We are so pleased that the Charit-EoE Concert for a Cure was able to assist in raising the funds to support these invaluable research grants to help us better understand EoE,” said Arlene and Lance Steinberg, organizers of the November fundraising event in New York City that benefited APFED’s HOPE Program. “The generous support of family, friends and many business associates helped further the quest for better therapies and ultimately a cure.”

APFED’s HOPE on the Horizon Research Program  launched in 2005 and is supported entirely by donations.  Contributions to the fund have enabled the organization to direct more than $2 million in support of research initiatives.

The HOPE Pilot Research Grants are competitive and are selected through a peer-review process. Applications are accepted from investigators from a variety of disciplines to initiate new projects relevant to eosinophil-associated diseases. Successful applications focus on the development of new ideas that are likely to lead to future external funding.

About American Partnership for Eosinophilic Disorders (APFED)

The American Partnership for Eosinophilic Disorders (APFED) is a non-profit organization whose mission is to passionately embrace, support, and improve the lives of patients and families affected by eosinophil-associated diseases through education and awareness, research, support, and advocacy. To learn more about APFED and eosinophil-associated diseases, visit apfed.org.

###

Celebrating APFED’s 15th Anniversary: Q&A with Founder Beth Allen

As APFED begins our 15th year, we caught up with APFED’s founder Beth Allen for a look back—and a look toward the future—with the woman who started it all.

Flashback with APFED founder Beth Allen and Eos community member Zach Brunnet
Flashback with APFED founder Beth Allen and Eos community
member Zach Brunnet

Describe what it was like to get a diagnosis 15 years ago. How long did the process take? What was available at the time?

Fifteen years ago, the ability to receive a diagnosis was heavily dependent on the physician’s exposure and education around eosinophil-associated disorders (EADs).  Eosinophilic esophagitis had not been coined EoE yet. It still went by EE and was often confused in paperwork as Erosive Esophagitis.  Patients often bounced through many physicians seeking help.  I had discussions with patients who had waited upwards of 10 to 20 years for a diagnosis and others who through persistence had ‘only’ waited 3 to 4 years.  There was a paper that came out in the early to mid- 2000s that estimated 4 to 6 years as average length of time to receive a diagnosis. This number has since come down dramatically.

The information available back then was a random personal blog that one could find buried in a Google search.  There was a paragraph available on a few web sites, and they cited the same information.  Eosinophils in large amounts in the gut.  Not much more.  Everything else patient-related was speculative in nature.  In 1999/2000 there were maybe 150-200 articles on EGIDs, and I printed most of them.  I read them and researched the medical terminology to understand the disease state.  I still have the binder with the articles.

The moment APFED was born was during a discussion with my son’s gastroenterologist.  He said, “Do not look this up as there is nothing credible out there for you.”  I immediately looked everything up.  There were a lot of contradicting web sites and minimal information.  That sentence and subsequent personal research led to the discussions with Jacque (Fanning) and Sherri (Herrick) and ultimately created APFED’s education and awareness path.

How were families able to connect in the early days without social media? What info was available online?

Early on, we created APFED online.  Jacque, Sherri and I had never met in person when the organization was formalized and realized.  We met after that point.  We all came to know one another on a YahooGroups chat board.  Facebook and similar entities were a long way off.  Back then, it was long threads of parents and patients telling their stories and people who had lived similarly. They helped calm you down and talked you through the anxiety of this mystery illness.  There was a heavy culture of empathy; we were all were sick and should not compare ourselves to each other.  That spirit also carried into the founding of the organization.
Truly, we originally wanted to simply have a camp but no camp would take us.  Conversations Jacque had went like this:

APFED’s First Annual Conference
APFED’s First Annual Conference

“We have a rare digestive disease and simply want to host a camp.  We can cover the necessary nurses.”

“Great.  We do hot dog cookouts.”

“No.  None of our kids can eat hot dogs.”

“Huh?  Okay. We also do ice cream socials.”

“No.  Can’t do those either.”

“We do a cookout.  What about chicken?”

“We don’t want the food.  Just the experience of being out together and building comradery.”

“Well, you might want to check with another camp because we aren’t sure we can accommodate you.”

Everything was food-centric.  From those pre-APFED conversations came the spirit of “it’s not about the food at the events but about the events themselves.”  No-food birthday cakes and celebrations began to take shape in the community.

Connecting was all on the message board and by telephone.  A lot of us began to schedule our trips for health care together so we could share expenses and the kids could meet others like themselves. Back then, you were lucky to be local to a physician who understood this disease.

A fundraiser in Florida from the early days
A fundraiser in Florida from the early days

What challenges did APFED face as a new nonprofit 15 years ago?

Financial was a big one.  One comes in feeling very altruistic and that people will understand the need to develop materials and spread the word but giving was small when we started.  We did a lot with the amount we had, and our first year was entirely dedicated to the first Patient Education Conference.  It was a chance for like-minded people to come together and know that they were not alone and to become educated from the few physicians that had adopted our rare corner of the world.

Another challenge was gaining acceptance that this was bigger than “they” said it was.  I had a physician tell me to my face, while laughing, that we were crazy to create APFED because eosinophilic disorders were THAT rare.

Our first grant enabled us to print brochures. The families involved were so dedicated that they would take those brochures to their local offices to help spread the word.  That still happens even now.  I remember taking my non-eos kid into an asthma/allergy office for a checkup and seeing one of our booklets on the table in the exam room. It came full circle very quickly, and I cried right there.

What are the top three improvements you have seen for our patient community over the last 15 years?

Obviously, “credible” information is now widely available.  You do not have to dig to get an education on these disorders anymore.  It is on Google, front and center. Physicians rely upon APFED more and more to be there for that daily support and education.

I was sitting in an office last September, and a family had just sat with the doctor who had performed a biopsy and told them their son likely had EoE. He knew my background and told them to ask me for information.  I wrote down APFED.org for them, and held the mom and grandma’s hands and told them their boy would be okay. This was NOT the end of the world and fortunately there is a group out there for them.

Another improvement is access to local care!  I love this.  Patients should not have to travel such distances to obtain care.

And, of course, the development of potential approved therapies.  I cross my fingers in the hope to see these passed ASAP!

What achievable goals can this community likely expect to see over the next 15 years?

This is what I hope for in the next 15 years:
•   Treatments.  Revise that to include safe, long-term treatments.
•    Additional states adopting mandates for coverage of medical foods (and not just for
infants/ young children)
•    The development of new, less invasive diagnostics?
•    A better understanding of the root cause of the disease?  Aside from the familial aspect, what is the catalyst that tips a person from fine to suddenly developing EoE/EGE?
•    More research in the lower gut.  I’m pretty passionate about that one.  It is desperately needed.
•    Lastly, transitional care programs.  My heart and passion still lies in that area of pediatric/adult gastroenterology.  The development of formalized programs that move a pediatric patient to the adult space without gaps.


Beth and Charlie Allen Today

Beth is now Director of Strategic Accounts for QOL Medical, a company that manufactures a sucrase enzyme replacement for patients with sucrose intolerance.  She leads pediatric gastroenterology initiatives at the hospital and national levels.

Beth’s son Charlie is now 17.  His eosinophilic disorders (EoE, EGE, EC) are still very up and down.  He was also diagnosed with a mitochondrial disorder in 2014. He had his g-tube taken out in 2011, but is still eating a limited diet. Charlie is active in choir and lacrosse and recently started an a capella club at his high school.  He still loves supporting other kids who have chronic health conditions.

Elimination Diet Research Study for Children

Has your child recently been diagnosed with EoE? Learn more about a new study looking at dietary therapy in children to see if your child is eligible to participate.
  •     Hear from patient advocates about the impact of this study in this video.
  •     Learn more about the benefits of participating in this study: Benefits Flyer
  •     Learn more about this study with a shareable flyer: Study Flyer
PCORI Locations Map 011817
Enrolling locations

Multi-Site Clinical Studies are Enrolling

Longitudinal Study

OMEGA: A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG) and Colitis (EC)

Ages 3-65

OMEGA Recruitment flyer on background Sep2016


Diet Study: Adults

SOFEED: Six Food vs One Food Eosinophilic Esophagitis Elimination Diet followed by Swallowed Glucocorticoid Trial

Ages 18-60

What is the most effective diet to treat EoE in adults? Could a less restrictive diet be as effective? The SOFEED clinical trial seeks to find answers to this question and more. Do you qualify to participate?

  •    Visit the CEGIR website to learn more about the SOFEED Study

SOFEED-WebGraphicKey6-15-16


Diet Study: Pediatrics

Ages 6-17

Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet followed by Swallowed Glucocorticoids

What is the most effective diet to treat EoE in children? Could a less restrictive diet be as effective? A new clinical trial open to children ages 6-17 seeks to find these answers. Learn more at rarediseasesnetwork.org/cms/pcori/.

  •     Learn more about this study with a shareable flyer: Study Flyer
  •     Hear from patient advocates about the impact of this study in this video.

dietstudyflier

 

PCORI Locations Map 011817
Enrolling locations